NEWTOWN, Mass. Novelos Therapuetics announced that the U.S. Patent and Trademark Office had issued a patent number for a compound named NOV-002.
“This most recent addition to our IP portfolio further strengthens Novelos’ proprietary position in the oxidized glutathione field in general and, in particular, around the structure of NOV-002,” said Christopher Pazoles, Ph.D, vice president of research and development of Novelos. “It will also allow us to expand our pipeline to include additional compounds based on this structural motif.”
This is Novelos lead compound in Phase 3 trial for non-small cell lung cancer. Novelos is a biopharmaceutical company focusing on the development of remedies for cancer and hepatitis.